{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:47:26Z","timestamp":1792144046429,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Drug Discov."],"DOI":"10.1038\/s44386-026-00085-y","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:17:05Z","timestamp":1790770625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized drug discovery from rare diseases to cancer"],"prefix":"10.1038","volume":"3","author":[{"given":"Vladimir L.","family":"Katanaev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"85_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJM199907013410106","volume":"341","author":"FS Collins","year":"1999","unstructured":"Collins, F. S. Shattuck lecture-medical and societal consequences of the Human Genome Project. N. Engl. J. Med. 341, 28\u201337 (1999).","journal-title":"N. Engl. J. Med."},{"key":"85_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrg.2016.86","volume":"17","author":"EA Ashley","year":"2016","unstructured":"Ashley, E. A. Towards precision medicine. Nat. Rev. Genet 17, 507\u2013522 (2016).","journal-title":"Nat. Rev. Genet"},{"key":"85_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s41591-026-04309-6","volume":"32","author":"DE Coral","year":"2026","unstructured":"Coral, D. E. et al. Five tenets for advancing evidence-based precision medicine. Nat. Med. 32, 1211\u20131222 (2026).","journal-title":"Nat. Med."},{"key":"85_CR4","doi-asserted-by":"crossref","unstructured":"Welzel, C., Ertaylan, G., Babina, I. S. & Gilbert, S. Regulating complexity in AI-enabled omics and multi-omics technologies for precision medicine. NPJ Digit. Med. 9,247 (2026).","DOI":"10.1038\/s41746-026-02553-1"},{"key":"85_CR5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","volume":"6","author":"C Luchini","year":"2020","unstructured":"Luchini, C., Lawlor, R. T., Milella, M. & Scarpa, A. Molecular tumor boards in clinical practice. Trends Cancer 6, 738\u2013744 (2020).","journal-title":"Trends Cancer"},{"key":"85_CR6","doi-asserted-by":"crossref","unstructured":"Larson, K. L. et al. Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis. Oncol. 5, PO.20.00495 (2021).","DOI":"10.1200\/PO.20.00495"},{"key":"85_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s44320-025-00125-1","volume":"21","author":"TV Denisenko","year":"2025","unstructured":"Denisenko, T. V. et al. Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers. Mol. Syst. Biol. 21, 952\u2013959 (2025).","journal-title":"Mol. Syst. Biol."},{"key":"85_CR8","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1111\/epi.16539","volume":"62","author":"SM Sisodiya","year":"2021","unstructured":"Sisodiya, S. M. Precision medicine and therapies of the future. Epilepsia 62, S90\u2013s105 (2021).","journal-title":"Epilepsia"},{"key":"85_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s44342-024-00032-1","volume":"22","author":"J Hong","year":"2024","unstructured":"Hong, J. et al. Rare disease genomics and precision medicine. Genomics Inform. 22, 28 (2024).","journal-title":"Genomics Inform."},{"key":"85_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1172\/JCI126119","volume":"129","author":"MJ Joyner","year":"2019","unstructured":"Joyner, M. J. & Paneth, N. Promises, promises, and precision medicine. J. Clin. Invest 129, 946\u2013948 (2019).","journal-title":"J. Clin. Invest"},{"key":"85_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3681","volume":"11","author":"JW Scannell","year":"2012","unstructured":"Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191\u2013200 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"85_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nrd3405","volume":"10","author":"F Pammolli","year":"2011","unstructured":"Pammolli, F., Magazzini, L. & Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428\u2013438 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"85_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40\u201351 (2014).","journal-title":"Nat. Biotechnol."},{"key":"85_CR14","doi-asserted-by":"publisher","first-page":"e2415445","DOI":"10.1001\/jamanetworkopen.2024.15445","volume":"7","author":"A Sertkaya","year":"2024","unstructured":"Sertkaya, A., Beleche, T., Jessup, A. & Sommers, B. D. Costs of drug development and research and development intensity in the US, 2000-2018. JAMA Netw. Open 7, e2415445 (2024).","journal-title":"JAMA Netw. Open"},{"key":"85_CR15","doi-asserted-by":"crossref","unstructured":"Baxter, K. et al. An end to the myth: There is no drug development pipeline. Sci. Transl. Med. 5, 171cm1 (2013).","DOI":"10.1126\/scitranslmed.3003505"},{"key":"85_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","volume":"19","author":"M Haendel","year":"2020","unstructured":"Haendel, M. et al. How many rare diseases are there? Nat. Rev. Drug Discov. 19, 77\u201378 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"85_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","volume":"14","author":"I Genitsaridi","year":"2026","unstructured":"Genitsaridi, I. et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diab. Endocrinol. 14, 149\u2013156 (2026).","journal-title":"Lancet Diab. Endocrinol."},{"key":"85_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02790-7","volume":"18","author":"LJ Fermaglich","year":"2023","unstructured":"Fermaglich, L. J. & Miller, K. L. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J. Rare Dis. 18, 163 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"85_CR19","unstructured":"National Academies of Sciences, E., and Medicine. Regulatory Processes for Rare Disease Drugs in the United States and European Union: Flexibilities and Collaborative Opportunities (The National Academies Press, 2024)."},{"key":"85_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.drudis.2021.10.014","volume":"27","author":"VM Alves","year":"2022","unstructured":"Alves, V. M. et al. Knowledge-based approaches to drug discovery for rare diseases. Drug Discov. Today 27, 490\u2013502 (2022).","journal-title":"Drug Discov. Today"},{"key":"85_CR21","doi-asserted-by":"publisher","unstructured":"de Gusmao, C. M., Katanaev, V. L., Silveira-Moriyama, L., Pringsheim, T. & Roze, E. Novel and emerging therapies for childhood-onset movement disorders. Mov Disord. https:\/\/doi.org\/10.1002\/mds.70495 (2026).","DOI":"10.1002\/mds.70495"},{"key":"85_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12325-025-03385-3","volume":"43","author":"LT Murray","year":"2026","unstructured":"Murray, L. T. et al. Study designs and crafting endpoints for gene therapy development programs in rare disease: a narrative review. Adv. Ther. 43, 76\u201397 (2026).","journal-title":"Adv. Ther."},{"key":"85_CR23","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.ymthe.2022.05.014","volume":"30","author":"BL Davidson","year":"2022","unstructured":"Davidson, B. L. et al. Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders. Mol. Ther. 30, 2416\u20132428 (2022).","journal-title":"Mol. Ther."},{"key":"85_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","volume":"1","author":"Y-H Chien","year":"2017","unstructured":"Chien, Y.-H. et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial.  Lancet Child Adolesc. Health 1, 265\u2013273 (2017).","journal-title":"Lancet Child Adolesc. Health"},{"key":"85_CR25","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1016\/j.cell.2025.06.038","volume":"188","author":"AA Sousa","year":"2025","unstructured":"Sousa, A. A. et al. In vivo prime editing rescues alternating hemiplegia of childhood in mice. Cell 188, 4275\u20134294.e4223 (2025).","journal-title":"Cell"},{"key":"85_CR26","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul, H. et al. Exagamglogene autotemcel for severe sickle cell disease. N. Engl. J. Med. 390, 1649\u20131662 (2024).","journal-title":"N. Engl. J. Med."},{"key":"85_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"85_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102432","volume":"36","author":"I Shomer","year":"2025","unstructured":"Shomer, I. et al. Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder. Mol. Ther. Nucleic Acids 36, 102432 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"85_CR29","doi-asserted-by":"publisher","unstructured":"Cocozza, G. et al. Gene supplementation therapy restores motor deficits in Gnao1[C215Y] mice and proves broad efficacy in C. elegans model. Acta Neuropathol. Commun. https:\/\/doi.org\/10.1186\/s40478-026-02389-6 (2026).","DOI":"10.1186\/s40478-026-02389-6"},{"key":"85_CR30","doi-asserted-by":"crossref","unstructured":"Crooke, S. T. et al. Addressing the needs of nano-rare patients: the n-Lorem experience. Nucleic Acids Res. 54, gkag504 (2026).","DOI":"10.1093\/nar\/gkag504"},{"key":"85_CR31","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.drudis.2022.01.013","volume":"27","author":"R Sakate","year":"2022","unstructured":"Sakate, R. & Kimura, T. Drug repositioning trends in rare and intractable diseases. Drug Discov. Today 27, 1789\u20131795 (2022).","journal-title":"Drug Discov. Today"},{"key":"85_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","volume":"42","author":"HI Roessler","year":"2021","unstructured":"Roessler, H. I., Knoers, N., van Haelst, M. M. & van Haaften, G. Drug repurposing for rare diseases. Trends Pharmacol. Sci. 42, 255\u2013267 (2021).","journal-title":"Trends Pharmacol. Sci."},{"key":"85_CR33","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.4103\/1673-5374.369106","volume":"18","author":"VL Katanaev","year":"2023","unstructured":"Katanaev, V. L., Valnohova, J., Silachev, D. N., Larasati, Y. A. & Koval, A. Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery. Neural Regen. Res. 18, 2188\u20132189 (2023).","journal-title":"Neural Regen. Res."},{"key":"85_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn9350","volume":"8","author":"YA Larasati","year":"2022","unstructured":"Larasati, Y. A. et al. Restoration of the GTPase activity and cellular interactions of G\u03b1(o) mutants by Zn(2+) in GNAO1 encephalopathy models. Sci. Adv. 8, eabn9350 (2022).","journal-title":"Sci. Adv."},{"key":"85_CR35","doi-asserted-by":"publisher","first-page":"100495","DOI":"10.1016\/j.medj.2024.07.023","volume":"6","author":"YA Larasati","year":"2025","unstructured":"Larasati, Y. A. et al. Zinc for GNAO1 encephalopathy: preclinical profiling and a clinical case. Med 6, 100495 (2025).","journal-title":"Med"},{"key":"85_CR36","doi-asserted-by":"publisher","first-page":"104092","DOI":"10.1016\/j.eclinm.2026.104092","volume":"98","author":"M Thiel","year":"2026","unstructured":"Thiel, M. et al. Safety and feasibility of oral zinc for patients with GNAO1-related disorders (ZINCGNAO1): an open-label, single-arm, single-centre, pilot trial in Germany. EClinicalMedicine 98, 104092 (2026).","journal-title":"EClinicalMedicine"},{"key":"85_CR37","doi-asserted-by":"crossref","unstructured":"Larasati, Y. A., Solis, G. P., Koval, A., Korff, C. & Katanaev, V. L. A personalized 14-3-3 disease-targeting workflow yields repositioning drug candidates. Cells 14, 559 (2025).","DOI":"10.3390\/cells14080559"},{"key":"85_CR38","doi-asserted-by":"crossref","unstructured":"Medina-Franco, J. L., L\u00f3pez-L\u00f3pez, E., Avellaneda-Tamayo, J. F. & Zamora, W. J. On the biologically relevant chemical space: BioReCS. Front. Drug Discov. 5, 1674289 (2025).","DOI":"10.3389\/fddsv.2025.1674289"},{"key":"85_CR39","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1021\/acs.jcim.0c00861","volume":"60","author":"A Edwards","year":"2020","unstructured":"Edwards, A. What are the odds of finding a COVID-19 drug from a lab repurposing screen? J. Chem. Inf. Model. 60, 5727\u20135729 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"85_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drudis.2018.06.012","volume":"24","author":"A Neuberger","year":"2019","unstructured":"Neuberger, A., Oraiopoulos, N. & Drakeman, D. L. Renovation as innovation: is repurposing the future of drug discovery research? Drug Discov. Today 24, 1\u20133 (2019).","journal-title":"Drug Discov. Today"},{"key":"85_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/21678707.2021.2047021","volume":"9","author":"KL Miller","year":"2022","unstructured":"Miller, K. L., Kraft, S., Ipe, A. & Fermaglich, L. Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies. Expert Opin. Orphan Drugs 9, 265\u2013272 (2022).","journal-title":"Expert Opin. Orphan Drugs"},{"key":"85_CR42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/d41573-026-00074-w","volume":"25","author":"J Fairnie","year":"2026","unstructured":"Fairnie, J. et al. Bridging boundaries: making drug repurposing the new normal. Nat. Rev. Drug Discov. 25, 663\u2013665 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"85_CR43","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1093\/jnci\/djaf193","volume":"117","author":"YC Kong","year":"2025","unstructured":"Kong, Y. C. et al. Global paid and unpaid productivity losses due to cancer-related mortality. J. Natl. Cancer Inst. 117, 2612\u20132620 (2025).","journal-title":"J. Natl. Cancer Inst."},{"key":"85_CR44","doi-asserted-by":"publisher","first-page":"j2765","DOI":"10.1136\/bmj.j2765","volume":"357","author":"B Cao","year":"2017","unstructured":"Cao, B. et al. Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981-2010. BMJ 357, j2765 (2017).","journal-title":"BMJ"},{"key":"85_CR45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-bioeng-110824-034150","volume":"28","author":"AD Laflin","year":"2026","unstructured":"Laflin, A. D., Pan, J., You, M. & Jiang, S. Recent advances in mRNA therapeutic cancer vaccines. Annu. Rev. Biomed. Eng. 28, 249\u2013272 (2026).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"85_CR46","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41591-026-04241-9","volume":"32","author":"JB Haanen","year":"2026","unstructured":"Haanen, J. B., Schumacher, T. N. M., Kagan, J. C., Fritsch, E. F. & Wu, C. J. Clinical development of cancer vaccines. Nat. Med. 32, 828\u2013840 (2026).","journal-title":"Nat. Med."},{"key":"85_CR47","doi-asserted-by":"crossref","unstructured":"Ye, L. et al. Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics. Signal Transduct. Target. Ther. 11, 285 (2026).","DOI":"10.1038\/s41392-026-02769-3"},{"key":"85_CR48","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"85_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/d41586-026-02680-5","volume":"657","author":"PA Ott","year":"2026","unstructured":"Ott, P. A. The Moderna cancer vaccine offers hope - now we must speed up personalized therapies. Nature 657, 10 (2026).","journal-title":"Nature"},{"key":"85_CR50","doi-asserted-by":"crossref","unstructured":"Slaney, C. Y. et al. Rewiring immunity with in vivo CAR T cell engineering. Nat. Cancer (2026).","DOI":"10.1038\/s43018-026-01216-0"},{"key":"85_CR51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41571-025-01115-w","volume":"23","author":"L Schultz","year":"2026","unstructured":"Schultz, L. et al. The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer. Nat. Rev. Clin. Oncol. 23, 260\u2013278 (2026).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"85_CR52","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski, K., Hill, J. A., Dahiya, S. & Jain, M. D. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat. Med. 31, 2132\u20132146 (2025).","journal-title":"Nat. Med."},{"key":"85_CR53","doi-asserted-by":"publisher","first-page":"101155","DOI":"10.1016\/j.gendis.2023.101155","volume":"11","author":"L Qi","year":"2024","unstructured":"Qi, L. et al. Twenty years of Gendicine\u00ae rAd-p53 cancer gene therapy: the first-in-class human cancer gene therapy in the era of personalized oncology. Genes Dis. 11, 101155 (2024).","journal-title":"Genes Dis."},{"key":"85_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3550","volume":"25","author":"B Cesur-Erg\u00fcn","year":"2023","unstructured":"Cesur-Erg\u00fcn, B. & Demir-Dora, D. Gene therapy in cancer. J. Gene Med. 25, e3550 (2023).","journal-title":"J. Gene Med."},{"key":"85_CR55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia, Y., Sun, M., Huang, H. & Jin, W. L. Drug repurposing for cancer therapy. Signal Transduct. Target. Ther. 9, 92 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"85_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2019.02.018","volume":"449","author":"K Ahmed","year":"2019","unstructured":"Ahmed, K., Koval, A., Xu, J., Bodmer, A. & Katanaev, V. L. Towards the first targeted therapy for triple-negative breast cancer: repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor. Cancer Lett. 449, 45\u201355 (2019).","journal-title":"Cancer Lett."},{"key":"85_CR57","doi-asserted-by":"publisher","first-page":"115539","DOI":"10.1016\/j.biopha.2023.115539","volume":"167","author":"J Xu","year":"2023","unstructured":"Xu, J., Koval, A. & Katanaev, V. L. Clofazimine: a journey of a drug. Biomed. Pharmacother. 167, 115539 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"85_CR58","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","volume":"5","author":"L Tong","year":"2024","unstructured":"Tong, L. et al. Patient-derived organoids in precision cancer medicine. Med 5, 1351\u20131377 (2024).","journal-title":"Med"},{"key":"85_CR59","doi-asserted-by":"crossref","unstructured":"Helal, C. et al. Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer. Cell Rep. Med. 7, 103011, (2026).","DOI":"10.1016\/j.xcrm.2026.103011"},{"key":"85_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26656","volume":"10","author":"MC Benedetti","year":"2024","unstructured":"Benedetti, M. C. et al. Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties. Heliyon 10, e26656 (2024).","journal-title":"Heliyon"},{"key":"85_CR61","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.medj.2023.03.001","volume":"4","author":"A Koval","year":"2023","unstructured":"Koval, A. et al. In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening. Med 4, 311\u2013325.e317 (2023).","journal-title":"Med"},{"key":"85_CR62","doi-asserted-by":"crossref","unstructured":"Larasati, Y. A., Koval, A. & Katanaev, V. L. Small-molecule inhibitor of G\u03b1o for GNAO1 encephalopathy. Biosci. Rep. 46, BSR20250392 (2026).","DOI":"10.1042\/BSR20250392"},{"key":"85_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40478-022-01312-z","volume":"10","author":"D Silachev","year":"2022","unstructured":"Silachev, D. et al. Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation. Acta Neuropathol. Commun. 10, 9 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"85_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54077-5","volume":"15","author":"O Kim-McManus","year":"2024","unstructured":"Kim-McManus, O. et al. A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases. Nat. Commun. 15, 9802 (2024).","journal-title":"Nat. Commun."},{"key":"85_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","volume":"24","author":"AH Jonker","year":"2025","unstructured":"Jonker, A. H. et al. The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nat. Rev. Drug Discov. 24, 40\u201356 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"85_CR66","doi-asserted-by":"crossref","unstructured":"Nolen, N. et al. Paying for precision: funding approaches for N-of-1 trials of individualized gene targeted therapies. Orphanet J. Rare Dis. 21, 281 (2026).","DOI":"10.1186\/s13023-026-04388-1"}],"container-title":["npj Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00085-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00085-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00085-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:13:48Z","timestamp":1792142028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00085-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1038\/s44386-026-00085-y","relation":{},"ISSN":["3005-1452"],"issn-type":[{"value":"3005-1452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"12 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The journal titles in References 9, 32, 35, 39, 47, 58, and 61 were incorrectly abbreviated. They have now been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"41"}}